Insightful (NASDAQ:IFUL)
Historical Stock Chart
From May 2019 to May 2024
Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive
analytics and reporting solutions, announced today the release and
immediate availability of version 1.1 of Insightful
Clinical Graphics (iCG), a product for defining and repurposing
statistical graphics across all functional areas in drug discovery,
development and marketing. iCG 1.1 features new graph types and an
improved user experience. Pharmaceutical companies currently starting
projects with iCG 1.1 include H. Lundbeck A/S in Denmark.
“Many global pharmaceutical companies are
looking to integrate graphics into their clinical trials process, making
iCG one of our most significant life science solutions to date,”
said Jeff Coombs, CEO of Insightful. “With
iCG, customers save time and resources, perform better scientific
analysis and interpretation, and communicate more effectively with
internal and external stakeholders.”
With input from multiple life sciences companies, Insightful designed
iCG to simplify the creation and re-use of statistical graphics and
elimination of redundant work processes. From discovery, pre-clinical
and clinical trials, through marketing and epidemiology, iCG enables
scientific data to be presented as actionable information in clinical
study reports, regulatory submissions, publications and presentations.
iCG helps optimize the deployment of expensive statistical programming
resources by allowing non-programming statisticians, clinicians and
medical writers to apply customizable graph templates to study data and
to change a graph style, without compromising the data or the results
displayed.
Key Features and Enhancements
iCG 1.1 contains a number of significant enhancements:
Expanded 2D graph palette, including bubble, delta, cumulative
incidence and double dot plots
Support for 3D graph types, including contour and image plots
Added plug-in customization of graph palette, graph metadata and
workflow
Improved user experience and system performance
Reduced dependence on Information Technology staff
Insightful Life Sciences Solutions Provide the Knowledge to Act™
Insightful provides life sciences organizations with the knowledge they
need to drive faster, better decisions, with specialized analytics,
graphics and reporting. Insightful offers software and service solutions
in statistical graphics, PK/PD analysis and reporting, clinical data
review, clinical trial design, and safety data analysis. These solutions
are designed to integrate with existing data management and workflow
systems in exploratory and validated environments, to speed the analysis
and reporting processes and increase the likelihood of discerning safety
and efficacy signals earlier in the drug development process, thus
decreasing customers’ product development
costs and time to market.
ABOUT INSIGHTFUL
Insightful Corporation (NASDAQ:IFUL) is a provider of predictive
analytics and reporting solutions. Insightful products S-PLUS®,
Insightful Miner™ and
S-PLUS® Enterprise
Server allow companies to perform sophisticated statistical data
analysis and data mining and create high-quality graphics and reports.
Insightful has been delivering industry-leading, high-ROI solutions to
thousands of companies in financial services, life sciences,
telecommunications, and manufacturing, plus government and research
institutions, for 20 years. Headquartered in Seattle, Insightful has
offices in New York, North Carolina, Switzerland, the United Kingdom,
France and Hong Kong, with distributors around the world. For more
information, visit www.insightful.com,
email info@insightful.com or
call 1-800-569-0123.
Note to Investors – Forward Looking
Statements
This press release contains forward-looking statements, including
statements about the potential performance and advantages of iCG and
other life sciences solutions and their potential value to customers.
Forward-looking statements are based on the judgment and opinions of
management at the time the statements are made. Inaccurate assumptions
and known and unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Actual results could differ materially from
those expressed or implied by the forward-looking statements for a
number of reasons, including, without limitation, the risk that our
products do not perform as designed and expected and the risk that our
products do not achieve market acceptance. More detailed information
regarding these and other factors that could affect actual results is
set forth in our filings with the Securities and Exchange Commission,
including our most recent report on Form 10-KSB. You should not unduly
rely on these forward-looking statements, which apply only as of the
date of this release. We undertake no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date of this release or to reflect the
occurrence of anticipated events.